Document is current
Any future updates will be listed below
-
Authors
Elliott, Amanda
Walters, Raymond K. https://orcid.org/0000-0001-8422-6530
Pirinen, Matti https://orcid.org/0000-0002-1664-1350
Kurki, Mitja
Junna, Nella https://orcid.org/0000-0002-5953-5523
Goldstein, Jacqueline I.
Reeve, Mary Pat
Siirtola, Harri
Lemmelä, Susanna M.
Turley, Patrick https://orcid.org/0000-0003-3643-8605
Lahtela, Elisa
Mehtonen, Juha https://orcid.org/0000-0003-0554-4667
Reis, Kadri
Elnahas, Abdelrahman G.
Reigo, Anu
Palta, Priit
Esko, Tõnu
Mägi, Reedik https://orcid.org/0000-0002-2964-6011
,
Metspalu, Andres
Nelis, Mari
Milani, Lili
Hudjashov, Georgi
,
Siirtola, Haari
Lahtinen, Elisa
Palotie, Aarno https://orcid.org/0000-0002-2527-5874
Daly, Mark J. https://orcid.org/0000-0002-0949-8752
Widén, Elisabeth https://orcid.org/0000-0001-7108-2806
- License Information
-
More Information
Article History
Received: 4 March 2023
Accepted: 7 November 2023
First Online: 5 January 2024
Competing interests
: R.K.W. has received honoraria from the Jackson Laboratory and sponsored travel from the Russell Sage Foundation. A.P. is the chief scientific officer for the FinnGen project, which has received funding from 13 pharmaceutical companies. M.J.D. is a founder of Maze Therapeutics. The remaining authors have no competing interests to declare.
